Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications [510(k)] with Different Technological Characteristics; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

1 organizations filed 1 public comment on Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications [510(k)] with Different Technological Characteristics; Draft Guidance for Industry and Food and Drug Administration Staff; Availability, at the Food and Drug Administration. The comment window closed 4305d ago.

Commenters (1)

• Advanced Medical Technology Associationtrade assoc.

  1 filing · confidence 97%